Canada-based clinical-stage biotech Zymeworks today announced positive top-line results from the Phase III HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) in combination with chemotherapy, ...

Established by ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, Arcera is redefining what it means to build a global healthcare company from the region.

Belgium-based Agomab Therapeutics today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase IIa clinical trial for ontunisertib (AGMB-129), an ...

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, today announced the close of its latest flagship fund, Sofinnova Capital XI, at 650 million euros ...

The European Federation of Pharmaceuticals Industries and Associations (EFPIA) and Vaccine Europe (VE) are calling for clear, predictable and supportive legislation under the upcoming EU Biotech Act, ...

Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed a Letter of Intent to jointly establish EarlyHealth City Barbados, a $200 million ...

Last week saw the end of the bidding war for Metsera, with the company accepting an improved offer from Pfizer and counter bidder Novo Nordisk pulling out. Also on Friday, Merck & Co announced a $9.2 ...

The European Medicines Agency’s EMA’s human medicines committee (CHMP) recommended seven novel medicines for approval at its November 2025 meeting.

Between the US government shutdown, crippling international tariffs, debilitating funding cuts to critical research, and the general policy whiplash in Washington DC, it's little wonder many US-based ...

Gate Bioscience has raised $65 million in an oversubscribed series B to advance its first molecular gate candidates, a novel class of oral small molecules designed to eliminate disease-driving ...

US medtech firm Terumo Blood and Cell Technologies has appointed Liza Loidolt as general manager of its cell and gene therapy business, marking a sharper strategic push into advanced therapeutics.

Merck & Co has struck a $9.2 billion deal to acquire biotechnology company Cidara Therapeutics in a move that bolsters the US pharma giant’s respiratory portfolio and pipeline as it braces for the ...